Clinical trials
Patients With Advanced Solid Tumors clinical trials
Below are recruiting patients with advanced solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,064 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07532018RecruitingPhase 1
DXP-106 Treatment for Advanced Solid Tumors
This early-stage trial tests a new drug called DXP-106 in patients with advanced cancers (like lung, pancreatic, or breast cancer) that have stopped responding to standard treatments. The study aims to find the right dose and see if this drug can help slow or shrink these tumors.
Harbin, HeilongjiangAges 18–75 - NCT07567222RecruitingPhase 1
Vaccine therapy for advanced solid tumors
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
Chengdu, SichuanAges 18–75 - NCT07577206RecruitingEarly Phase 1
New PET Scan Tracer for Advanced Solid Cancers
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Naples, ItaliaAges 18 years+ - NCT07610798RecruitingPhase 1/Phase 2
Testing INV-8989 for Advanced Cancers With KRAS G12D Mutation
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07636200Recruiting
Managing Fear and Worry in Advanced Cancer
This study tests a new approach to help people with advanced cancer who feel significant fear about their cancer getting worse or coming back. The program uses writing and therapeutic techniques to help reduce this fear and related stress.
Aurora, ColoradoAges 18 years+ - NCT07638371RecruitingPhase 1
MSK-TCR5 Cell Therapy for RAS G12D Solid Tumors
This study tests a new type of cell therapy called MSK-TCR5, designed to fight solid cancers (like pancreatic, lung, or colon cancer) that have a specific RAS G12D mutation. The therapy uses your own immune cells trained to recognize and attack cancer cells with this mutation.
Basking Ridge, New JerseyAges 18 years+ - NCT07645261RecruitingPhase 2
Lattice Radiation for Large Tumors When Other Treatments Won't Help
This trial tests a special type of focused radiation therapy (called SBRT-Lattice) for large tumors in patients who can't benefit from surgery, chemotherapy, or standard radiation. The radiation uses a lattice pattern designed to treat the tumor while protecting healthy tissue nearby.
São Paulo, São PauloAges 18 years+ - NCT07656090Enrolling by invitationEarly Phase 1
Testing IDOV-Immune for advanced solid tumors
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT05691517RecruitingPhase 1
Test drug CBX-12 in advanced cancers and monitor your response
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Bethesda, MarylandAges 18 years+ - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+ - NCT07705035RecruitingPhase 1
DBC-664 for adults with advanced solid tumors
This trial tests a new drug called DBC-664 for people with solid tumors that have come back or spread and cannot be removed by surgery. It may be an option if you have tried other treatments or if standard options are limited.
Denver, ColoradoAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06868199RecruitingPhase 1/Phase 2
Testing LM-168 with or without toripalimab for advanced solid tumors
This study tests a new drug called LM-168, either alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that haven't responded to standard treatments. It aims to see if this combination is safe and effective, and may offer a new option when others have stopped working.
Ryde, New South WalesAges 18 years+ - NCT06031584RecruitingPhase 1/Phase 2
Testing BL-M07D1 for HER2-positive or low solid tumors
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07446816RecruitingPhase 1
Study of hemay181 for advanced solid tumors
This trial tests a new drug, Hemay181, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it can shrink tumors and how safe it is.
Xinxiang, HenanAges 18–75 - NCT05579275RecruitingEarly Phase 1
Study JCXH-212 to treat advanced solid tumors safely
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Beijing, Beijing MunicipalityAges 18–75 - NCT07274813RecruitingEarly Phase 1
Study of HLX37 for advanced solid tumors that haven't responded to treatment
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
ShanghaiAges 18–75 - NCT07475182RecruitingEarly Phase 1
Cell therapy for advanced solid tumors with specific proteins
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
Haikou, HainanAges 18–75 - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04925609RecruitingPhase 1/Phase 2
Brigatinib for young people with ALK-positive cancer
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
ParisAges 1–25 - NCT05615974RecruitingPhase 1/Phase 2
LM-101 injection study for advanced solid tumors
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
Guangzhou, GuangdongAges 18 years+
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patients with advanced solid tumors?
- Yes. Clin2 currently lists 1,064 recruiting patients with advanced solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patients with advanced solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patients with advanced solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Advanced Solid Tumor
- Advanced Malignant Solid Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.